Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697473 | 0.83 | BLM (0.48) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA | |
| SCHEMBL4861916 | 0.80 | BLM (0.46) | L3MBTL1SMN1; SMN2BLMCYP2D6ALDH1A1 | |
| SCHEMBL745452 | 0.79 | CYP2C19 (0.56) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA | |
| SCHEMBL5929556 | 0.79 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA | |
| SCHEMBL28888936 | 0.79 | SMN1; SMN2 (0.47) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA | |
| SCHEMBL17743682 | 0.79 | CYP2C19 (0.47) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA | |
| SCHEMBL6570728 | 0.79 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA | |
| SCHEMBL6570465 | 0.76 | MEN1 (0.52) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA | |
| SCHEMBL9809364 | 0.75 | HDAC6 (0.44) | SMN1; SMN2 | |
| SCHEMBL5929588 | 0.75 | L3MBTL1 (0.47) | L3MBTL1SMN1; SMN2BLMCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819359-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | Centocor, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006062779-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | CENTOCOR, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | JANSSEN BIOTECH, INC. | 2006-06-15 | — | — | US | claimed |
| EP-1395290-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | claimed |
| US-7361347-B2 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-22 | — | — | US | disclosed |
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | ADOLF GUENTHER | 2005-12-08 | — | — | US | disclosed |
| EP-1395290-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | disclosed |
| US-4919927-A | Using ammonium chloride | SANOFI (FR) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | L3MBTL1 977/4885SMN1; SMN2 2871/4885BLM 4654/4885 |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | L3MBTL1 977/4885SMN1; SMN2 2871/4885BLM 4654/4885 |
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | ITGB3, ITGB5, ITGB4 | L3MBTL1 3155/4885SMN1; SMN2 2872/4885BLM 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.